Successful treatment of recurrent immunoglobulin a nephropathy using steroid pulse therapy plus tonsillectomy 10 years after kidney transplantation: a case presentation

Haruki Katsumata1*, Izumi Yamamoto1, Yo Komatsuzaki1, Mayuko Kawabe1, Yusuke Okabayashi1, Takafumi Yamakawa1, Ai Katsuma1, Yasuyuki Nakada1, Akimitsu Kobayashi1, Yudo Tanno1, Jun Miki2, Hiroki Yamada2, Ichiro Ohkido1, Nobuo Tsuboi1, Hiroyasu Yamamoto3 and Takashi Yokoo1

Abstract

Background: Both prevention and treatment of recurrent immunoglobulin A nephropathy (IgAN) in kidney transplant recipients are important since recurrent IgAN seems to affect long-term graft survival. We present here a case of recurrent IgAN that was successfully treated using steroid pulse therapy plus tonsillectomy 10 years after kidney transplantation.

Case presentation: A 46-year-old male was admitted for an episode biopsy with a serum creatinine level of 1.8 mg/dl and proteinuria (0.7 g/day). Histological features showed recurrent IgAN (only focal segmental mesangial proliferation) and severe arteriolar hyalinosis partly associated with calcineurin inhibitor toxicity, with limited interstitial fibrosis and tubular atrophy (5%) (IF/TA) 8 years after transplantation. Sodium restriction and conversion from cyclosporine to tacrolimus successfully reduced his proteinuria to the level of 0.15 g/day. However, 2 years later, his proteinuria increased again (1.0 g/day) and a second episode biopsy showed global mesangial proliferation with glomerular endocapillary and extracapillary proliferation accompanied by progressive IF/TA (20%). The steroid pulse therapy plus tonsillectomy successfully decreased his proteinuria and he achieved clinical remission 3 years after this treatment.

Conclusion: This case, presented with a review of relevant literature, demonstrates the difficulty and importance of the treatment of recurrent IgAN and calcineurin inhibitor arteriolopathy, especially in long-term kidney allograft management.

Keywords: IgA nephropathy, Kidney transplantation, Tonsillectomy, Steroid, Calcineurin inhibitor nephrotoxicity, Case report

* Correspondence: sprttree@gmail.com
1Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, Tokyo 105-8461, Japan
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Immunoglobulin A nephropathy (IgAN) is a common recurrent glomerulonephritis that affects transplanted kidney allograft survival. The rate of allograft loss at 10 years is similar with IgAN and other glomerulonephritids [1]. However, a recent study showed that graft survival in patients with IgAN has gradually worsened and death-censored graft survival at 15 years was approximately 10% lower compared with other glomerulonephritids [2]. Steroid pulse therapy is the standard treatments for recurrent IgAN, but difficult to manage, especially in long-term kidney allograft. We here report a case of IgAN that reoccurred 10 years after kidney transplantation, which was successfully treated. In addition, this case showed severe arteriolar hyalinosis partly induced by long-term use of calcineurin inhibitors (CNIs). CNI arteriolopathy affects allograft survival; some investigators have tried to withdraw or avoid these drugs, as their use is now controversial. We also review this important problem.

Case presentation
A 46-year-old Japanese man was admitted to our hospital for an episode kidney allograft biopsy because his proteinuria and serum creatinine had increased at the level of 0.7 g/day and 1.8 mg/dl, respectively. His first kidney biopsy was performed at 19 years of age for proteinuria and hematuria (this biopsy result could not be obtained). However, he had not received any treatment for his kidney disease. After 16 years, he presented at our hospital with a visual loss caused by hypertensive retinopathy, and blood examination showed end-stage renal disease. After undergoing peritoneal dialysis for 1.5 years, he received a living-related kidney transplantation from his mother when he was 36 years old. ABO blood types were compatible. The immunosuppressive therapy consisted of tacrolimus, mycophenolate mofetil, and basiliximab. The allograft demonstrated excellent early function, with a serum creatinine (S-Cr) level and proteinuria of 1.5 mg/dl and 0.2–0.3 g/day, respectively. The 1-month and 1-year protocol biopsy showed neither evidence of rejection nor recurrence of primary disease. However, he developed pure red cell aplasia caused by parvovirus; therefore, tacrolimus was converted to cyclosporine and he recovered from this infection immediately. His S-Cr levels increased to 1.8 mg/dl, with the appearance of proteinuria (0.7 g/day) 8 years post transplantation. A first episode biopsy was performed and histopathology showed no evidence of rejection with limited interstitial fibrosis and tubular atrophy (5%). However, global sclerosis was observed in 15 out of 36 glomeruli (42%). The rest of the conserved glomeruli showed focal segmental mesangial proliferation with IgA deposition. Of note, severe arteriolar hyalinosis partly associated with CNI arteriolopathy was evident (Banff 2013 classification: t0, i0, g0, v0, ptc0, ct1, ci0, cg0, cv0, aah3). He was diagnosed with recurrence of IgAN (Oxford classification: M1, E1, T0) and severe arteriolar hyalinosis. We estimated that the patient had no active lesion due to IgAN because there was neither endocapillary nor extracapillary proliferation. On the other hand, 42% of global sclerosis seems to be led by severe arteriolar hyalinosis (Fig. 1). Because he had already taken angiotensin II receptor blocker, we did not administer further drugs. Dietary sodium restriction and conversion of cyclosporine to tacrolimus reduced urinary protein to the level of 0.15 g/day.

However, 2 years later (10 years after transplantation), he presented proteinuria again at the level of 1.0 g/day accompanied by microscopic hematuria (urinary red blood cell count was 5–9/high-power field). Therefore, a second episode biopsy was performed. Histopathology showed diffuse global mesangial proliferation and mild interstitial fibrosis (20%); moreover, endocapillary and extracapillary hypercellularity was evident in two out of 19 glomeruli (Fig. 2). In the mesangium, immunofluorescence revealed multiple immunoreactivities for IgA, immunoglobulin M (IgM), complement component 3 (C3), and complement component 1, q subcomponent (C1q). We diagnosed recurrence of IgA nephropathy again and the Oxford classification showed a higher score (M1, S1, E1, T1) than in the first episode biopsy. This recurrence had happened despite taking immunosuppressive drugs and histologically worsened than first time recurrence after kidney transplantation. These findings predicted disease progression and poor prognosis. Therefore, we considered steroid pulse therapy plus tonsillectomy was more effective in this case than steroid pulse therapy alone. He received tonsillectomy first due to his work’s schedule (He could hospitalize only at this time). Because steroid pulse therapy immediately after tonsillectomy had been reported to increase the bleeding episodes, he received steroid pulse therapy (methylprednisolone 500 mg/day × 3 days × 3 times) few months later. After the treatment, his proteinuria gradually decreased and was maintained around 0.3 g/day for 3 years after started therapy (Fig. 3).

Discussion
Recurrent glomerulonephritis is an important problem affecting transplanted kidney allograft survival. A previous report showed no significant differences in allograft loss at 10 years with IgAN and other glomerulonephritis [1]. However, Moroni et al. demonstrated that graft survival in patients with IgAN had become gradually worse and death-censored graft survival at 15 years was approximately 10% lower compared with that in controls (62.6%
Fig. 1 First episode biopsy was performed 8 years after transplantation. Light microscopy showed no evidence of rejection. (a) A segmental mesangial hypercellularity can be seen. (b) An immunofluorescence study showed mild-to-moderate positivity in the mesangial area for IgA. Positivity for IgM and C3 was also seen (not shown). (c) An arteriolar hyalinosis caused by CNI nephrotoxicity was remarkable. (d) Two branches of severe arteriolar hyalinosis seemed to develop global glomerular sclerosis.

Fig. 2 Second episode biopsy that was performed 10 years after transplantation also showed no evidence of rejection. (a), (b) Extracapillary proliferations were observed in 2 of 19 glomeruli. (c) A global mesangial proliferations and endocapillary proliferations were seen.
Furthermore, in this retrospective study, IgAN recurred in 22.1% of patients and these patients had a worse prognosis compared with non-recurrent IgAN patients; therefore, poor outcomes in IgAN patients are likely to be caused by its recurrence. Recurrence is an important cause of allograft loss in other glomerulonephritis as in IgAN, but IgAN especially worsened as noted in long-term observation [3]. Thus, aggressive medical treatment for recurrent IgAN in long-term transplant recipients is required to improve graft outcomes.

In native kidney biopsies, endocapillary proliferation is known to be a risk factor for the progression of IgAN [4]. In addition, a previous study that evaluated the outcome in recurrent IgAN after transplantation had demonstrated proteinuria (more than 1 g/day), elevation of S-Cr level, and pathological findings of more than 30% glomerulosclerosis and interstitial fibrosis were the risk factor of disease progression [5, 6]. In our case, first episode biopsy showed increased S-Cr level from 1.5 to 1.8 mg/dl and histopathology showed 42%(>30%)glomerulosclerosis. In line with such reports, our case showed disease progression for the 2 years after the first episode biopsy. However, we did not treat for recurrent IgAN because the disease activity was not clearly evident at first biopsy.

Interventional solutions for recurrent IgAN in kidney transplant recipients have not been sufficiently studied; therefore, these patients should be treated similarly as non-transplant IgAN patients at present. However, kidney transplant recipients have already taken multiple immunosuppressants and hence recurrent IgAN often becomes more difficult to treat, so we performed tonsillectomies in addition to steroid pulse therapy. Various methods of steroid pulse therapy based on dose, dosing period, and interval have been proposed at present. Our method was based on the protocol that Pozzi et al. had reported previously [7]. Although it is still controversial whether tonsillectomy should be performed in IgAN, we consider that tonsillectomy combined with steroid pulse therapy is the better treatment of IgAN for several reasons. First, tonsillectomy has been reported to be safe surgery whose mortality rate is much low (0.0006%) [8]. Other reports also showed low risk of tonsillectomy (the prevalence rate of bleeding: 1.3–2.9%) [9–15]. Second, tonsillectomy can remove abnormal polymeric IgA1, which is known as the pathogenesis of IgAN [16]. A combined tonsillectomy and steroid pulse therapy is thought to be effective to decrease the production of polymeric IgA1 by both removal of tonsils and suppression of plasma cells. Finally, several studies have clinically revealed the efficacy of combined therapy. The recent prospective randomized-control study showed that in native kidneys, the percentage decrease in proteinuria at 12 months was better in combination with steroid pulse therapy and tonsillectomy compared to that with steroid therapy alone. Although the clinical remission rate was not significantly different between steroid therapy plus tonsillectomy and steroid therapy alone, the combined therapy was the independent factor contributing to the disappearance of proteinuria (odds ratio 2.98) [17]. Similarly, a more recent meta-analysis that included 14 studies (1794 patients) noted
that the remission rate of proteinuria was better in the combination therapy (odds ratio 3.15) [18]. Additionally, recent randomized controlled study has examined the effect of steroid pulse therapy combined with tonsillectomy on clinical remission by pathological sub-analysis. This study has suggested that combined therapy has a greater benefit of clinical remission than steroid therapy alone in the moderate to severe pathological case that showed more than 25% of glomeruli exhibiting crescents, segmental sclerosis or global sclerosis (odds ratio 8.17) [19]. Our case also matched these criteria (42.1%: two crescents and 6 global sclerosis was observed in 19 glomeruli). In this context, tonsillectomy in addition to steroid pulse therapy seems beneficial in recurrent IgAN as well. Several case reports and retrospective cohorts showed the proteinuria-reducing effects of tonsillectomy in transplant recipients [20, 21]. In our case, proteinuria was improved after steroid pulse therapy plus tonsillectomy. Therefore, we should consider performing tonsillectomy if the disease is progressive or difficult to treat by other therapy. However, based on the previous report that evaluated the preventive effects of pretransplant tonsillectomy on IgAN recurrence, tonsillectomy may not be useful for preventing IgA recurrence [22].

Another important issue as shown in this case was CNI toxicity. Histopathology showed severe arteriolar hyalinosis partly associated with CNI toxicity. Low dose tacrolimus is less harmful than cyclosporine in both renal and non-renal organ transplantation [23, 24]. Ojo et al. reported that the relative risk associated with cyclosporine was 1.24 [25]. Therefore, we reconverted cyclosporine to tacrolimus after the first episode renal biopsy. CNI withdrawal or avoidance is a well-known risk factor for graft rejection. A recent prospective study that tried to taper the tacrolimus dose in stable transplant recipients became difficult to continue because of high rates of acute rejection (4 of 14 patients) and de novo donor-specific antibody appearance (5 of 14 patients) [26]. Therefore, change from CNI to mammalian target of rapamycin inhibitor (mTORi) may be the alternative treatment. In fact, some investigators reported improvement in glomerular filtration rate after change to mTORi, without any increase in graft rejection [27, 28]. However, a systematic review of randomized control studies showed that the risk of rejection at 1 year is higher in mTORi-based treatment (relative risk 1.72) [29]. Additionally, Gallon L et al. reported that T-cell alloreactivity increased after switching tacrolimus to sirolimus, which indicates that conversion runs the risk of graft rejection [30]. Hence, we did not convert to mTORi in this case.

Conclusion
We present that steroid pulse therapy plus tonsillectomy is effective even in patients with long-term recurrent IgAN. Managing long-term CNI toxicity is another important issue. Prospective studies are needed to assess the efficacy of such management in cases of long-term kidney allograft.

Abbreviations
CNI: calcineurin inhibitor, IgAN: immunoglobulin A nephropathy; mTORi: mammalian target of rapamycin inhibitor

Acknowledgements
The authors thank Moe Ishida for her excellent technical assistance with immunohistochemistry.

Author contribution
YK, MK, YO, AK, YT and IO participated the nephropathy treatment. HK participated the clinical practice and drafted the manuscript. YJ and YN participated the nephropathy treatment and revised the manuscript. JM and HIROKI YAMADA performed the kidney transplantation. TN diagnosed the nephropathy. HIROYASU YAMAMOTO is an outpatient physician. TAKASHI YOKOO is the divisional director and supervised each author. All the authors contributed to preparation of the manuscript, and approved the final version.

Funding
The authors declare no conflicts of interest associated with this manuscript.

Availability of data and materials
All the data supporting our findings is contained within the manuscript.

Competing interest
The authors declare that they have no competing interests.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, Tokyo 105-8461, Japan. 2Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. 3Department of Internal Medicine, Atsugi City Hospital, Kanagawa, Japan.

Received: 18 August 2016 Accepted: 23 February 2018
Published online: 14 March 2018

References
1. Briganti EM, Russ GR, McNeil JJ, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med. 2007;347:103–9.
2. Moroni G, Longhi S, Quaglini S, et al. The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival. Nephrol Dial Transplant. 2013;28:1305–14.
3. Mulay AV, van Waarde C, Kroll GA. Impact of immunosuppressive medication on the risk of renal allograft failure due to recurrent glomerulonephritis. Am J Transplant. 2009;9:804–11.
4. Catran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534–45.
5. Kimata N, Tanabe K, Ishikawa N, et al. Correlation between proteinuria and prognosis of transplant IgA nephropathy. Transplant Proc. 1996;28:1537–9.
6. Ponticelli C, Traversi L, Feliciani A, et al. Kidney transplantation in patients with IgA mesangial glomerulonephritis. Kidney Int. 2001;60:1948–54.
7. Pozzi C, Andrucci S, Del Vecchio L, Meli P, Fogazzi GB, Alteri P, Ponticelli C, Locatelli F. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004 Jan;15(1):157–63.
8. Pratt LW. Tonsillectomy and Adenoidectomy: mortality and morbidity. Trans Am Acad Ophthalmol Otolaryngol. 1970;74:1146–54.
9. Windfuhr JP, Chen YS. Post-tonsillectomy and -adenotonsillectomy hemorrhage in nonselected patients. Ann Otol Rhinol Laryngol. 2003;112:63–70.
10. Lowe D, van der Meulen J, et al. Tonsillectomy technique as a risk factor for postoperative haemorrhage. Lancet. 2004;364:697–702.
11. Walker P, Gillies D, et al. Post-tonsillectomy hemorrhage rates: are they technique-dependent? Otolaryngol Head Neck Surg. 2007;136(Suppl):S27–31.
12. Arndtner C, Grasl MC, Thurnher D, et al. Surgical revision of hemorrhage in 8388 patients after cold-steel adenotonsillectomies. Wien Klin Wochenschr. 2008;120:336–42.
13. Hessén Söderman AC, Ericsson E, Hemlin C, et al. Reduced risk of primary postoperative hemorrhage after tonsil surgery in Sweden: results from the National Tonsil Surgery Register in Sweden covering more than 10 years and 54,696 operations. Laryngoscope. 2011;121:2322–6.
14. Tomkinson A, Harrison W, Owens D, et al. Risk factors for postoperative hemorrhage following tonsillectomy. Laryngoscope. 2011;121:279–88.
15. Kennoki T, Ishida H, Yamaguchi Y, et al. Proteinuria-reducing effects of tonsillectomy alone in IgA nephropathy recurring after kidney transplantation. Transplantation. 2009;88:935–41.
16. Giannakakis K, Feriozzi S, Perez M, et al. Aberrantly glycosylated IgA1 in glomerular immune deposits of IgA nephropathy. J Am Soc Nephrol. 2007;18:3139–46.
17. Kawamura T, Yoshimura M, Miyazaki Y, et al. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin a nephropathy. Nephrol Dial Transplant. 2014;29:1546–53.
18. Liu LL, Wang LN, Jiang Y, et al. Tonsillectomy for IgA nephropathy: a meta-analysis. Am J Kidney Dis. 2015;65:80–7.
19. Katafuchi R, Kawamura T, Joh K, et al. Pathological sub-analysis of a multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy versus steroid pulse monotherapy in patients with immunoglobulin a nephropathy. Clin Exp Nephrol. 2016;20:44–52.
20. Tsuchiya T, Ito S, Yamaguchi Y, et al. Tonsillectomy and steroid pulse therapy for recurrent IgA nephropathy in renal allograft. Clin Nephrol. 2010;73:68–71.
21. Ushigome H, Suzuki T, Fujiki M, et al. Efficacy of tonsillectomy for patients with recurrence of IgA nephropathy after kidney transplantation. Clin Transpl. 2009;23 Suppl 1:207–12.
22. Sato Y, Ihida H, Shimizu T, et al. Evaluation of tonsillectomy before kidney transplantation in patients with IgA nephropathy. Transpl Immunol. 2014;30:12–7.
23. Elbergh, T, Tedesco-Silla H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562–75.
24. Shihab FS, Waid Th, Conti DJ. Conversion from cyclosporine to tacrolimus in nonrenal organ. N Engl J Med. 2003;349:931.
25. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931–40.
26. Hick DE, Formica RN, Nickerson P, et al. Adverse outcomes of tacrolimus withdrawal in immune-quesant kidney transplant recipients. J Am Soc Nephrol. 2015;26:1114–22.
27. Buddle K, Becker T, Arns W, et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet. 2013;377:837–47.
28. Weir MR, Mulgaonkar S, Chan L, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled spare-the-nephron trial. Kidney Int. 2011;79:987–907.
29. Lim WH, Eris J, Kanellis J, et al. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. Am J Transplant. 2014;14:2106–19.
30. Gallon L, Traitanon O2, Sustento-Redica N, et al. Cellular and molecular immune profiles in renal transplant recipients after conversion from tacrolimus to sirolimus. Kidney Int. 2015;87:828–38.